Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid-1 Receptor (CB1R) Inverse Agonist

Journal of Clinical Pharmacology

Volumn 49, Issue 10, 2009, Pages 1228-1238

  Addy, Carol ^a   Jumes, Patricia ^a   Rosko, Kimberly ^a   Li, Susie ^a   Li, Hankun ^a   Maes, Andrea ^a   Johnson Levonas, Amy O ^a   Chodakewitz, Jeffrey ^a   Stoch, S Aubrey ^a   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cannabinoid 1 receptor inverse agonist; Pharmacokinetics; Phentermine; Taranabant

Indexed keywords

PHENTERMINE; TARANABANT;

ABDOMINAL PAIN; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEART RATE; HUMAN; MALE; NAUSEA; NORMAL HUMAN; PR INTERVAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AMIDES; ANTI-OBESITY AGENTS; BLOOD PRESSURE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG INVERSE AGONISM; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PHENTERMINE; PYRIDINES; RECEPTOR, CANNABINOID, CB1;

EID: 70349518919     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009341651     Document Type: Article

References (26)

1. World Health Organization (WHO). Obesity Fact Sheet. Geneva, Switzerland: WHO ; 2008.
2. Wechsler Adult Intelligence Scale-Revised. San Antonio, TX: Psychological Corporation ; 1981.
3. Bray GA, Greenway FL Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007 ; 59: 151-184.
4. Torretta LK Dexfenfluramine, fenfluramine, and phentermine for the treatment of morbid obesity. J Am Acad Nurse Pract. 1997 ; 9: 389-394, quiz.
5. Seghatol FF, Rigolin VH Appetite suppressants and valvular heart disease. Curr Opin Cardiol. 2002 ; 17: 486-492.
6. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990 ; 346: 561-564.
7. Howlett AC The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002 ; 68-69: 619-631.
8. Kirkham TC, Tucci SA Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets. 2006 ; 5: 272-292.
9. Kirkham TC Endogenous cannabinoids: a new target in the treatment of obesity. Am J Physiol Regul Integr Comp Physiol. 2003 ; 284: R343 - R344.
10. Addy C., Wright H., Van Laere K., et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 2008 ; 7: 68-78.
11. Lin LS, Lanza TJ Jr, Jewell JP, et al. Discovery of N-[(1S,2S)-3-(4- Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl) pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem. 2006 ; 49: 7584-7587.
12. Fong TM, Guan XM, Marsh DJ, et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3- cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy] propanamide (MK-0364), in rodents. J Pharmacol Exp Ther. 2007 ; 321: 1013-1022.
13. Gantz I., Erondu N., Suryawanshi S., et al. A two year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results. JACC. 2008 ; 1021: A326.
14. Proietto J., Rissanen A., Harp J., et al. Safety and efficacy of taranabant, a highly selective CB1-R inverse agonist, over one year in obese and overweight patients with obesity-related comorbidities. Obesity. 2008 ; 16: S63.
15. Kipnes M., Hollander P., Gantz I., et al. A one-year study to assess the efficacy, safety, and tolerability of taranabant, a highly selective CB1-R inverse agonist, in overweight and obese patients with type 2 diabetes: 36-week results. Obesity. 2008 ; 16: S293.
16. Davidson MH, McKenney JM, Bays HE, et al. The efficacy and tolerability of taranabant, a cannabinoid receptor inverse agonist, over 24 weeks in obese patients. Int J Obes. 2008 ; 32: S89.
17. Addy C., Cote J., Li S., et al. Taranabant plasma concentrations increased when co-administered with ketoconazole or diltiazem. Obes Program Abstract Suppl. 2007 ; 15: A147 - A148.
18. Addy C., Cote J., Li S., et al. Taranabant exhibits no clinically meaningful effect on the pharmacokinetic profile of midazolam. Obes Program Abstract Suppl. 2007 ; 15: A147.
19. von Moltke LL, Greenblatt DJ, Ciraulo DA, et al. Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine. J Clin Psychopharmacol. 1998 ; 18: 338-341.
20. Duncan JD, Cho AK N-oxidation of phentermine to N-hydroxyphentermine by a reconstituted cytochrome-P-450 oxidase system from rabbit liver. Mol Pharmacol. 1982 ; 22: 235-238.
21. Addy C., Rothenberg P., Li S., et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J Clin Pharmacol. 2008 ; 48: 734-744.
22. Kroenke K., Spitzer RL, Williams JB The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 ; 16: 606-613.
23. Kroenke K., Spitzer RL, Williams JB The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002 ; 64: 258-266.
24. Ahearn EP The use of visual analog scales in mood disorders: a critical review. J Psychiatr Res. 1997 ; 31: 569-579.
25. Baker F., Denniston M., Zabora J., Polland A., Dudley WN A POMS short form for cancer patients: psychometric and structural evaluation. Psychooncology. 2002 ; 11: 273-281.
26. Addy C., Li S., Agrawal N., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J Clin Pharmacol. 2008 ; 48: 418-427.